Eric Rovner to Treatment Outcome
This is a "connection" page, showing publications Eric Rovner has written about Treatment Outcome.
Connection Strength
1.560
-
Update on Urethral Bulking for Stress Urinary Incontinence in Women. Curr Urol Rep. 2022 Oct; 23(10):203-209.
Score: 0.092
-
Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. Neurourol Urodyn. 2020 02; 39(2):744-753.
Score: 0.077
-
One-year results with selective bladder denervation in women with refractory overactive bladder. Neurourol Urodyn. 2019 11; 38(8):2178-2184.
Score: 0.075
-
Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence. J Urol. 2019 05; 201(5):967-972.
Score: 0.074
-
A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology. Contemp Clin Trials. 2018 07; 70:83-87.
Score: 0.069
-
Three-month primary efficacy data for the SUCCESS Trial; a phase III, multi-center, prospective, randomized, controlled study treating female stress urinary incontinence with the vesair intravesical balloon. Neurourol Urodyn. 2018 01; 37(1):440-448.
Score: 0.067
-
Outcomes of treatment of stress urinary incontinence associated with female urethral diverticula: A selective approach. Neurourol Urodyn. 2018 01; 37(1):478-484.
Score: 0.065
-
Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review. Neurourol Urodyn. 2017 Sep; 36(7):1677-1684.
Score: 0.063
-
Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment. J Urol. 2016 Sep; 196(3):801-8.
Score: 0.060
-
Outcomes of Autologous Fascia Pubovaginal Sling for Patients with Transvaginal Mesh Related Complications Requiring Mesh Removal. J Urol. 2016 Aug; 196(2):484-9.
Score: 0.059
-
Simple vs complex urethral diverticulum: presentation and outcomes. Urology. 2014 Dec; 84(6):1516-9.
Score: 0.054
-
Chapter 6: Practical aspects of administration of onabotulinumtoxinA. Neurourol Urodyn. 2014 Jul; 33 Suppl 3:S32-7.
Score: 0.053
-
OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013 Nov; 32(8):1109-15.
Score: 0.048
-
Sling location in women with recurrent stress urinary incontinence following midurethral sling. Urology. 2012 Jan; 79(1):76-9.
Score: 0.044
-
Managing complications of slings. Curr Opin Urol. 2011 Jul; 21(4):291-6.
Score: 0.043
-
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011 Apr; 30(4):556-62.
Score: 0.042
-
An update on surgery for pelvic organ prolapse. Curr Opin Urol. 2010 Nov; 20(6):490-4.
Score: 0.041
-
Frequently asked questions in the evaluation and management of overactive bladder. J Fam Pract. 2009 Oct; 58(10 Suppl):S1-11; quiz S12.
Score: 0.038
-
Stress incontinence surgery: which operation when? Curr Opin Urol. 2009 Jul; 19(4):362-7.
Score: 0.037
-
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008 Sep; 180(3):1034-41.
Score: 0.035
-
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology. 2008 Sep; 72(3):488-93.
Score: 0.035
-
Female urethral strictures: successful management with long-term clean intermittent catheterization after urethral dilatation. BJU Int. 2006 Jul; 98(1):96-9.
Score: 0.030
-
The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW. Value Health. 2005 Nov-Dec; 8 Suppl 1:S25-34.
Score: 0.029
-
Bone anchors for stress urinary incontinence in 2004: con. Urology. 2004 Nov; 64(5):851-4.
Score: 0.027
-
Pharmacologic management of urinary incontinence in the female. Minerva Ginecol. 2004 Aug; 56(4):327-47.
Score: 0.027
-
Update on overactive bladder: pharmacologic approaches on the horizon. Curr Urol Rep. 2003 Oct; 4(5):385-90.
Score: 0.025
-
Does urinary urgency drive urinary frequency in overactive bladder? Low Urin Tract Symptoms. 2022 Jul; 14(4):242-247.
Score: 0.022
-
Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol. 2002 Jan; 41(1):6-14.
Score: 0.022
-
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021 Oct; 13(4):425-434.
Score: 0.021
-
Treatments used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology. 2000 Dec 20; 56(6):940-5.
Score: 0.021
-
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). Adv Ther. 2019 08; 36(8):1906-1921.
Score: 0.019
-
Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive Bladder. J Urol. 2019 03; 201(3):573-580.
Score: 0.018
-
Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence. Neurourol Urodyn. 2019 02; 38(2):825-837.
Score: 0.018
-
Study design and outcomes measures: The influence of composite endpoints and other design variables on outcomes in a study of a novel device for stress urinary incontinence. Neurourol Urodyn. 2018 11; 37(8):2919-2927.
Score: 0.018
-
Why anti-incontinence surgery succeeds or fails. Clin Obstet Gynecol. 1998 Sep; 41(3):719-34.
Score: 0.018
-
Twelve-Month Efficacy and Safety Data for the "Stress Incontinence Control, Efficacy and Safety Study": A Phase III, Multicenter, Prospective, Randomized, Controlled Study Treating Female Stress Urinary Incontinence Using the Vesair Intravesical Balloon. Female Pelvic Med Reconstr Surg. 2018 May/Jun; 24(3):222-231.
Score: 0.017
-
Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60.
Score: 0.010
-
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb; 107(4):612-20.
Score: 0.010
-
Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010 Jan; 183(1):234-40.
Score: 0.010
-
Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 2010 May; 105(9):1268-75.
Score: 0.010
-
Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006 May; 97(5):1003-6.
Score: 0.007
-
Continence mechanism based on a modified ileocecal valve. Tech Urol. 2000 Sep; 6(3):167-71.
Score: 0.005
-
Artificial urinary sphincter for post-prostatectomy incontinence: impact of prior collagen injection on cost and clinical outcome. J Urol. 2000 Jan; 163(1):87-90.
Score: 0.005